Silver Nanoparticle Investigation for Treating Chronic Sinusitis
Status:
Withdrawn
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Chronic rhinosinusitis is a highly prevalent disease resulting in high economic burden.
Effective therapeutic options are needed. Rhinosinusitis-related biofilms are a likely
contributor to recalcitrant disease. Emerging evidence shows that colloidal silver
nanoparticles may be effective for reducing biofilms. The investigators intend to perform a
randomized, double-blinded, placebo-controlled clinical trial to evaluate the effectiveness
and safety of intranasal colloidal silver nanoparticles in adult patients with chronic
rhinosinusitis. The investigators hypothesize that compared to placebo, treatment with
intranasal colloidal silver for chronic rhinosinusitis will lead to a significant improvement
in symptom scores and will not be associated with increased rate of adverse effects.